Morgan Stanley’s Alpine Immune Sciences Inc ALPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-789,645
| Closed | -$31.3M | – | 8026 |
|
|
2024
Q1 | $31.3M | Sell |
789,645
-647,837
| -45% | -$19.1M | ﹤0.01% | 2206 |
|
|
2023
Q4 | $27.4M | Buy |
1,437,482
+1,384,009
| +2,588% | +$19.2M | ﹤0.01% | 3072 |
|
|
2023
Q3 | $612K | Buy |
53,473
+3,269
| +7% | +$40.2K | ﹤0.01% | 5077 |
|
|
2023
Q2 | $516K | Buy |
50,204
+22,290
| +80% | +$201K | ﹤0.01% | 5196 |
|
|
2023
Q1 | $215K | Buy |
27,914
+10,353
| +59% | +$82.5K | ﹤0.01% | 5676 |
|
|
2022
Q4 | $129K | Buy |
17,561
+5,999
| +52% | +$38.3K | ﹤0.01% | 5865 |
|
|
2022
Q3 | $84K | Sell |
11,562
-1,637
| -12% | -$13.5K | ﹤0.01% | 6170 |
|
|
2022
Q2 | $112K | Buy |
13,199
+3,922
| +42% | +$33.8K | ﹤0.01% | 6216 |
|
|
2022
Q1 | $83K | Buy |
9,277
+132
| +1% | +$1.14K | ﹤0.01% | 6442 |
|
|
2021
Q4 | $127K | Buy |
9,145
+6,411
| +234% | +$79.4K | ﹤0.01% | 6302 |
|
|
2021
Q3 | $28K | Sell |
2,734
-592
| -18% | -$5.46K | ﹤0.01% | 6967 |
|
|
2021
Q2 | $30K | Sell |
3,326
-2,024
| -38% | -$22K | ﹤0.01% | 6864 |
|
|
2021
Q1 | $57K | Sell |
5,350
-372,373
| -99% | -$4.64M | ﹤0.01% | 6296 |
|
|
2020
Q4 | $4.76M | Buy |
377,723
+375,306
| +15,528% | +$3.68M | ﹤0.01% | 3309 |
|
|
2020
Q3 | $21K | Sell |
2,417
-1,658
| -41% | -$15.2K | ﹤0.01% | 6052 |
|
|
2020
Q2 | $40K | Buy |
4,075
+4,068
| +58,114% | +$17.6K | ﹤0.01% | 5754 |
|
|
2020
Q1 | $0 | Sell |
7
-14
| -67% | -$44 | ﹤0.01% | 6754 |
|
|
2019
Q4 | $0 | Sell |
21
-4
| -16% | -$12 | ﹤0.01% | 6813 |
|
|
2019
Q3 | $0 | Sell |
25
-6,854
| -100% | -$29.4K | ﹤0.01% | 6804 |
|
|
2019
Q2 | $29K | Buy |
6,879
+341
| +5% | +$1.97K | ﹤0.01% | 5821 |
|
|
2019
Q1 | $45K | Sell |
6,538
-1,146
| -15% | -$7.14K | ﹤0.01% | 5717 |
|
|
2018
Q4 | $29K | Buy |
7,684
+6,647
| +641% | +$32.8K | ﹤0.01% | 5937 |
|
|
2018
Q3 | $7K | Hold |
1,037
| – | – | ﹤0.01% | 6383 |
|
|
2018
Q2 | $8K | Sell |
1,037
-406
| -28% | -$3.35K | ﹤0.01% | 6357 |
|
|
2018
Q1 | $11K | Buy |
1,443
+406
| +39% | +$4.01K | ﹤0.01% | 6242 |
|
|
2017
Q4 | $12K | Sell |
1,037
-1,500
| -59% | -$16.3K | ﹤0.01% | 6191 |
|
|
2017
Q3 | $29K | Sell |
2,537
-2,675
| -51% | -$25K | ﹤0.01% | 5944 |
|
|
2017
Q2 | $50K | Buy |
5,212
+4,751
| +1,031% | +$45.5K | ﹤0.01% | 5860 |
|
|
2017
Q1 | $5K | Sell |
461
-638
| -58% | -$6.46K | ﹤0.01% | 6363 |
|
|
2016
Q4 | $10K | Sell |
1,099
-1,863
| -63% | -$37.1K | ﹤0.01% | 6160 |
|
|
2016
Q3 | $96K | Sell |
2,962
-1,361
| -31% | -$33.1K | ﹤0.01% | 5321 |
|
|
2016
Q2 | $79K | Sell |
4,323
-2,827
| -40% | -$50.2K | ﹤0.01% | 5351 |
|
|
2016
Q1 | $119K | Buy |
7,150
+6,931
| +3,165% | +$139K | ﹤0.01% | 5230 |
|
|
2015
Q4 | $7K | Sell |
219
-8,534
| -97% | -$291K | ﹤0.01% | 6323 |
|
|
2015
Q3 | $454K | Buy |
+8,753
| New | +$575K | ﹤0.01% | 4665 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 6780 |
|
Morgan Stanley's ALPN Position: Q2 2024 in Review
Morgan Stanley sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 789,645 shares — an estimated $31.3M sold.
Morgan Stanley first reported a position in ALPN in Q3 2015 and held it in 35 quarters. The position peaked at $31.3M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.
- Morgan Stanley reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
- Morgan Stanley sold 789,645 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $31.3M.
- Morgan Stanley first reported a position in Alpine Immune Sciences Inc in Q3 2015 and held it in 35 quarters.
- Morgan Stanley's Alpine Immune Sciences Inc position peaked at $31.3M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.
Based on Morgan Stanley's 13F filing for Q2 2024, filed 14 Aug 2024.